News

Emory University researchers have confirmed that hydroxyurea, a widely used oral chemotherapy drug, remains a safe and effective long-term treatment for children with sickle cell disease (SCD). A study tracking …

AB Science has received a U.S. patent for masitinib in treating sickle cell disease (SCD), with protection extending to 2040. The approval follows compelling preclinical results showing masitinib’s efficacy against …

New long-term data from the BELIEVE trial confirm that luspatercept, manufactured by Bristol Myers Squibb, provides lasting benefits for patients with transfusion-dependent beta-thalassemia, significantly reducing the need for frequent blood …

Actinium Pharmaceuticals, Inc. is making progress with Iomab-ACT, an experimental treatment designed to improve stem cell transplants for sickle cell disease (SCD). The therapy uses targeted radiation to clear diseased …

Bristol Myers Squibb receives European Commission approval for Opdivo® + Yervoy® as a first-line treatment for adult patients with unresectable or advanced hepatocellular carcinoma. The Phase 3 CheckMate -9DW trial …

Agios Pharmaceuticals is progressing with its Phase 3 RISE UP trial for Pyrocaine (mitapivat) in sickle cell disease, with results expected by end of 2025. The study aims to demonstrate …

Novo Nordisk is advancing etavopivat for sickle cell disease, aiming to reduce vaso-occlusive crises (VOCs) by 50% in a Phase 3 trial next year. The drug came from Novo’s $1.1 …

Roxadustat, a breakthrough anemia treatment, is set for further expansion in China as AstraZeneca acquires full rights from FibroGen in a $160 million deal. Originally developed to treat anemia from …

Agios Pharmaceuticals continues its commitment to expanding the use of Pyrukynd (mitapivat) for patients with thalassemia and sickle cell disease, two conditions with significant unmet medical needs. In recent Phase …